Navigation Links
Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis

groups at weeks 8 and 12 versus approximately 10% reduction for placebo. Statistically significant differences as compared to placebo were not achieved for the erythema or pruritus scores which were less severe at baseline.

The drug was well-tolerated across both active treatment arms, and there were no reports of drug-related serious adverse events.

"Although we just missed statistical significance for the primary endpoint, we are pleased with these results given the limited number of patients in the study. These results are consistent with data from previous studies of liarozole in this rare debilitating disease," commented Geert Cauwenbergh, Ph.D., Chief Executive Officer of Barrier Therapeutics. "These data provide additional support for the potential efficacy and safety of the class of retinoic acid metabolizing blocking agents (RAMBAs), which inhibit the body from breaking down its own retinoic acid, the active form of vitamin A, a key nutrient for healthy skin. While Barrier has no plans to further develop this product candidate itself, we intend to provide the data to U.S. and European regulatory authorities and to companies focused on orphan drugs."

About Liarozole

Liarozole is a novel compound that belongs to a new class of drugs known as retinoic acid metabolism blocking agents, or RAMBAs. Retinoic acid, also known as vitamin A, is essential for optimal functioning of the skin. In contrast to current synthetic retinoid treatments, which introduce man-made forms of vitamin A into the body, RAMBAs work by slowing the metabolism or degradation of the body's own retinoic acid. This causes the body to maintain higher, potentially therapeutic levels of this natural vitamin in cells of the skin. Based on this mechanism of action and early clinical data, we believe that this class of drugs could be effective in treating skin diseases and conditions, such as congenital ichthyosis, psoriasis, acne and photo-damage, which result from abno
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:10/30/2014)... --  NxStage® Kidney Care, Inc ., a subsidiary of NxStage® ... host the grand opening ceremony of its Oak ... Street on November 20, 2014 from 3pm – 7pm. The ... who are committed to providing patients with enhanced access to ... through more flexible dialysis treatment options.   The ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014  Electronic ... dramatically as a result of government initiatives and ... - healthcare providers have invested over the past ... heart of health IT, and U.S. clinicians use ... Logo - http://photos.prnewswire.com/prnh/20141029/155278LOGO ...
(Date:10/30/2014)... 2014  Nektar Therapeutics (Nasdaq: NKTR ) ... ended September 30, 2014 on Thursday, November 6, 2014, ... Robin , president and chief executive officer, will host ... 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... audio-only Webcast of the conference call can be accessed ...
Breaking Medicine Technology:Grand Opening of NxStage Kidney Care Oak Brook IL Center 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 3Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2
(Date:10/30/2014)... 30, 2014 REV'D Provision Co. announced ... available through a unique service called, The Feed ... empower the everyday athlete. The Feed has taken the ... created a system to pass that information on to ... is now available on The Feed!” says REV’D® marketing ...
(Date:10/30/2014)... The Woodlands, TX (PRWEB) October 30, 2014 ... hospital system, released today its 2014 third quarter ... hospitals across Texas boasted infection rates of only ... also reported patient satisfaction scores exceeding 98 percent. ... this past quarter, which included rising satisfaction scores,” ...
(Date:10/30/2014)... (HealthDay News) -- Scientists who used stem cells to ... breakthrough could provide a new way to learn more ... The team used human pluripotent stem cells -- which ... -- to grow the functional miniature stomachs, to study ... cause of ulcers and stomach cancer. The miniature ...
(Date:10/30/2014)... -- Many U.S. colleges have indoor tanning salons ... the risk for skin cancer, researchers report. ... women, so colleges should adopt tanning-free policies, to ... "Public health efforts are needed to raise university ... that indoor tanning poses to young adults in ...
(Date:10/30/2014)... 2014 (HealthDay News) -- A new vaccine that could ... was approved by the U.S. Food and Drug Administration ... between the ages of 10 and 25 from invasive ... B bacteria. The bacteria can infect the bloodstream ... and brain. It is a leading cause of bacterial ...
Breaking Medicine News(10 mins):Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:FDA Approves New Vaccine to Protect Against Meningitis 2
... (ZixCorp(R)), (Nasdaq: ZIXI ), the leader in hosted ... corporate update by its chief executive officer, Rick Spurr. , ... ZixCorp and we are on target to report within the ... are that we should meet our revenue guidance of $7.3 ...
... 7 The National Inflation Association today released the following ... , "It is becoming increasingly likely that health care will ... There is no doubt about it that health care costs ... the government to do something about astronomical health care costs, ...
... , ,PROVIDENCE, R.I. [Brown University] Fueling the debate ... or repressed memory, Brown University political scientist Ross Cheit ... issue is how to prove whether the memories of ... and then resurface later in life. Cheit,s paper, co-authored ...
... Providence Service Corporation (Nasdaq: PRSC ) today commented ... state,s attempt to close its large budget deficit. ... our programs in California are primarily funded by Medicaid and ... do not expect to experience material funding issues for our ...
... study findings , TUESDAY, July 7 (HealthDay News) -- ... findings that show a reduced-dose schedule for the pneumococcal ... , The current recommended dose schedule for 7-valent pneumococcal ... the age of 6 months, followed by a booster ...
... less pain with conventional operation , TUESDAY, July 7 (HealthDay ... that can be caused by sciatica didn,t work as well ... expected treatment benefit of a faster rate of recovery from ... double-blind study," according to a report in the July 8 ...
Cached Medicine News:Health News:Zix Corporation CEO Provides Corporate Update for Second Quarter 2009 2Health News:Zix Corporation CEO Provides Corporate Update for Second Quarter 2009 3Health News:Zix Corporation CEO Provides Corporate Update for Second Quarter 2009 4Health News:NIA Says Health Care Will Cause U.S. Dollar Collapse 2Health News:NIA Says Health Care Will Cause U.S. Dollar Collapse 3Health News:Brown professor continues debate over recovered memory 2Health News:Providence Service Corporation Does Not Expect California Budget Issues to Materially Impact Its Business in the State 2Health News:Fewer Shots Could Still Protect Kids From Pneumonia 2Health News:Minimally Invasive Surgery Not Better for Sciatica 2Health News:Minimally Invasive Surgery Not Better for Sciatica 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: